Agency Information Collection Activities: Proposed Collection; Comment Request, 27339-27341 [2019-12340]

Download as PDF Federal Register / Vol. 84, No. 113 / Wednesday, June 12, 2019 / Notices Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Rebecca Steiner Garcia, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6149, MSC 9608, Bethesda, MD 20892, 301–443–4525, steinerr@mail.nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel; R34 Refinement and Testing of Interventions to Sustain ADHD Treatment Effects. Date: July 10, 2019. Time: 12:30 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Karen Gavin-Evans, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6153, MSC 9606, Bethesda, MD 20892, 301–443–2356, gavinevanskm@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) Dated: June 7, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–12368 Filed 6–11–19; 8:45 am] Dated: June 7, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–12369 Filed 6–11–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–P Substance Abuse and Mental Health Services Administration DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency Information Collection Activities: Proposed Collection; Comment Request National Institutes of Health National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. jbell on DSK3GLQ082PROD with NOTICES Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Room 2114, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Ranga Srinivas, Ph.D., Chief Extramural Project Review Branch, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 6700 B Rockledge Drive, Room 2114, Bethesda, MD 20892, (301) 451–2067, srinivar@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards., National Institutes of Health, HHS) Name of Committee: National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; Mechanistic Studies on Chronic Alcohol and Sleep R01 Review Panel RFA–AA–19–006. Date: July 26, 2019. Time: 11:00 a.m. to 2:00 p.m. VerDate Sep<11>2014 17:00 Jun 11, 2019 Jkt 247001 In compliance with section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276– 1112. Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use PO 00000 Frm 00109 Fmt 4703 Sfmt 4703 27339 of automated collection techniques or other forms of information technology. Proposed Project: 2020 National Survey on Drug Use and Health Clinical Validation Study and Redesign Field Test (OMB No. 0930–0110)—Revision to 2019 NSDUH Collection The National Survey on Drug Use and Health (NSDUH) is a survey of the U.S. civilian, non-institutionalized population aged 12 years old or older. The data are used to determine the prevalence of use of tobacco products, alcohol, illicit substances, and illicit use of prescription drugs. The results are used by SAMHSA, the Office of National Drug Control Policy (ONDCP), federal government agencies, and other organizations and researchers to establish policy, direct program activities, and better allocate resources. 2020 NSDUH Main Study— NSDUH must be updated periodically to reflect changing substance use and mental health issues and to continue producing current data. For the 2020 NSDUH main study the following changes from 2019 are planned: (1) The addition of lifetime and recency questions about vaping anything and vaping nicotine or tobacco; the addition of lifetime and recency questions on synthetic marijuana and synthetic stimulants; (2) the addition of questions in concordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth edition criteria (DSM–5) to measure the occurrence of marijuana withdrawal symptoms, occurrence of prescription tranquilizer misuse withdrawal symptoms and occurrence of craving for all substances; (3) minor revisions to the marijuana marketplace module; and (4) other minor wording changes to improve the flow of the interview, increase respondent comprehension or to be consistent with text in other questions. By including these new questions in NSDUH, estimates may be generated on the use of these substances among the general population and allow SAMHSA to provide national-level estimates among adults and adolescents on the use of vaping, synthetic marijuana, and synthetic stimulants. In addition, because NSDUH collects demographic, socioeconomic, and health information about each respondent, the inclusion of these questions would permit a more detailed understanding of factors associated with their use. The new questions on craving for all substances and withdrawal for marijuana/cannabis were added to the 2020 NSDUH main study to reflect the updated DSM–5 diagnostic criteria for substance use disorders. Questions E:\FR\FM\12JNN1.SGM 12JNN1 27340 Federal Register / Vol. 84, No. 113 / Wednesday, June 12, 2019 / Notices measuring withdrawal for tranquilizers have been added to ensure SUD for tranquilizers is accurately assessed as well. The marijuana marketplace module (originally dropped in the 2015 redesign questionnaire) was reinserted in the NSDUH main study questionnaire starting in 2018 at the request of ONDCP but was unchanged from the version previously used in the 2014 NSDUH. (This module was not part of the NSDUH questionnaire from 2015–2017.) This module consists of a series of questions that seek to gather data such as the location, quantity, cost and type of marijuana being purchased across the nation. Revisions have been made to this module for 2020 to reflect the availability that marijuana can now be purchased from a retail store or dispensary. As with all NSDUH/NHSDA surveys conducted since 1999, the sample size of the NSDUH main study for 2020 will be sufficient to permit prevalence estimates for each of the fifty states and the District of Columbia. (Prior to 2002, the NSDUH was referred to as the National Household Survey on Drug Abuse (NHSDA).) The total annual burden estimate for the NSDUH main study is shown below in Table 1. TABLE 1—ANNUALIZED ESTIMATED BURDEN FOR 2020 NSDUH Number of respondents Instrument Responses per respondent Total number of responses Hours per response Total burden hours Household Screening ........................................................... Interview ............................................................................... Screening Verification .......................................................... Interview Verification ............................................................ 143,255 69,007 4,348 10,351 1 1 1 1 143,255 69,007 4,348 10,351 0.083 1.000 0.067 0.067 11,890 69,007 291 694 Total .............................................................................. 143,255 ........................ 226,961 ........................ 81,882 Clinical Validation Study— In addition, a Clinical Validation Study (CVS) is planned to be embedded within the first six months of 2020 NSDUH main study data collection to assess revisions to the substance use disorders (SUD) module to be consistent with the DSM–5. The CVS will examine the validity of this revised NSDUH assessment of SUD by administering questions to adults and adolescents who will then be interviewed by clinical interviewers (who are blinded to the NSDUH main study responses) and classified as having or not having substance use disorders based on past year DSM–5 disorders, as assessed by the Structured Clinical Interview for DSM–5 (SCID–5). During CVS data collection from January through June 2020, approximately 1,500 NSDUH main study interview respondents will be selected for a follow-up clinical interview at the end of the main study interview in order to produce a final sample size of approximately 825 CVS respondents. These follow-up clinical interviews will be conducted via telephone using the SCID–5 within two to four weeks following the NSDUH main study interview. Many of the procedures and protocols planned for inclusion in this CVS are based upon those previously employed as part of the 2018 National Mental Health Study (approved under OMB No. 0930–0380) and the 2008–2012 NSDUH Mental Health Surveillance Study (approved as an add-on to NSDUH under OMB No. 0930–0110). Also, to complete training prior to CVS data collection, each clinical interviewer candidate hired must successfully administer the follow-up clinical interview with a volunteer respondent. These 70 certification interviews will be administered in the same manner as CVS follow-up clinical interviews. The total annual burden estimate for the CVS is shown below in Table 2. TABLE 2—ANNUALIZED ESTIMATED BURDEN FOR 2020 NSDUH CVS Number of respondents jbell on DSK3GLQ082PROD with NOTICES Instrument Responses per respondent Total number of responses Hours per response Total burden hours Follow-Up Clinical Interviews ............................................... Follow-Up Clinical Certifications .......................................... 826 70 1 1 826 70 0.83 0.83 686 58 Total .............................................................................. 896 ........................ 896 ........................ 744 Redesign Field Test— Also, as part of SAMHSA’s ongoing effort to ensure NSDUH continues producing current and accurate data, a Redesign Field Test (FT) is planned from August through November 2020 to assess potential revisions to the NSDUH main study questionnaire. These revisions are designed to address changing policy and research data needs; in addition, modifications to associated survey materials and methods are designed to improve the VerDate Sep<11>2014 17:00 Jun 11, 2019 Jkt 247001 quality of estimates and the efficiency of data collection. Planned FT modifications include changes to respondent incentives, respondent materials, the household screening questionnaire, the interview questionnaire, and other data collection methods. The FT is essential for providing a thorough examination of these planned changes prior to their deployment on the NSDUH main study to determine potential impact across operational and PO 00000 Frm 00110 Fmt 4703 Sfmt 4703 substantive domains, including effects on data quality (as measured by outcomes such as unit nonresponse, item nonresponse, and survey responses), questionnaire timing, data collection efficiency, and possible differences in reporting of substance use or mental health items. During FT data collection from August through November 2020, conducted separately from ongoing 2020 NSDUH main study data collection at that time, screenings will be completed E:\FR\FM\12JNN1.SGM 12JNN1 27341 Federal Register / Vol. 84, No. 113 / Wednesday, June 12, 2019 / Notices with approximately 8,110 Englishspeaking respondents in the contiguous United States. (Alaska and Hawaii are excluded from the FT to control study costs.) From those screenings, approximately 4,000 respondents, as representatives of the civilian, noninstitutional population aged 12 years old or older, are expected to complete a FT interview using the revised questionnaire and materials. For the NSDUH FT screening, revisions may include: (1) A revised roster structure; (2) various wording edits to improve respondent comprehension and flow; (3) the use of revised materials, such as the lead letter, study description and question & answer brochure; (4) a conditional test of a $5 screening incentive to assess impact on response rates; and (5) the inclusion of two outcome questions on past month alcohol and past month cigarette use at the end of the screening to assess nonresponse bias from the screening incentive. For the NSDUH FT interview, revisions may include: (1) A conditional test of a $50 interview incentive to assess impact on response rates; (2) revisions to the DSM–5-based SUD module as a result of prior testing in the CVS; (3) the inclusion of new modules on substance use treatment and mental health service utilization; (4) the addition of new and/or revised questions on a variety of items such as Electronic Nicotine Delivery Systems (ENDS), synthetic drugs, pain and sleep, vaping and needle use, and criminal justice; (5) the addition of measures of adolescent psychological distress and/or impairment; (6) the expansion of suicide items; and (7) other general questionnaire revisions such as clarifying wording and terminology, reordering for improved question flow, formatting changes, removal of questions with low prevalence rates, and other minor updates and revisions. The total annual burden estimate for the FT is shown below in Table 3. TABLE 3—ANNUALIZED ESTIMATED BURDEN FOR REDESIGN FIELD TEST Number of respondents Instrument Total number of responses Hours per response Total burden hours Household Screening ........................................................... Interview ............................................................................... Screening Verification .......................................................... Interview Verification ............................................................ 8,110 4,000 246 600 1 1 1 1 8,110 4,000 246 600 0.083 1.000 0.067 0.067 673 4,000 17 40 Total .............................................................................. 8,110 ........................ 12,596 ........................ 4,730 Send comments to Janet Heekin, SAMHSA Reports Clearance Officer, Room 15E21B, 5600 Fishers Lane, Rockville, MD 20857 or email a copy at janet.heekin@samhsa.hhs.gov. Written comments should be received by August 12, 2019. Dated: June 6, 2019. Carlos Castillo, Committee Management Officer. Comments must reach the Coast Guard on or before August 12, 2019. DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2019–0353] Information Collection Request to Office of Management and Budget; OMB Control Number: 1625–0049 Coast Guard, DHS. Sixty-day notice requesting comments. AGENCY: ACTION: In compliance with the Paperwork Reduction Act of 1995, the U.S. Coast Guard intends to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting an extension of its approval for the SUMMARY: 17:00 Jun 11, 2019 You may submit comments identified by Coast Guard docket number [USCG–2019–0353] to the Coast Guard using the Federal eRulemaking Portal at https://www.regulations.gov. See the ‘‘Public participation and request for comments’’ portion of the SUPPLEMENTARY INFORMATION section for further instructions on submitting comments. A copy of the ICR is available through the docket on the internet at https:// www.regulations.gov. Additionally, copies are available from: Commandant (CG–612), Attn: Paperwork Reduction Act Manager, U.S. Coast Guard, 2703 Martin Luther King Jr. Ave. SE, Stop 7710, Washington, DC 20593–7710. ADDRESSES: BILLING CODE 4162–20–P VerDate Sep<11>2014 following collection of information: 1625–0049, Waterfront Facilities Handling Liquefied Natural Gas (LNG) and Liquefied Hazardous Gas (LHG); without change. Our ICR describe the information we seek to collect from the public. Before submitting this ICR to OIRA, the Coast Guard is inviting comments as described below. DATES: [FR Doc. 2019–12340 Filed 6–11–19; 8:45 am] jbell on DSK3GLQ082PROD with NOTICES Responses per respondent Jkt 247001 Mr. Anthony Smith, Office of Information Management, telephone 202–475–3532, or fax 202–372–8405, for questions on these documents. FOR FURTHER INFORMATION CONTACT: SUPPLEMENTARY INFORMATION: PO 00000 Frm 00111 Fmt 4703 Sfmt 4703 Public Participation and Request for Comments This notice relies on the authority of the Paperwork Reduction Act of 1995; 44 U.S.C. Chapter 35, as amended. An ICR is an application to OIRA seeking the approval, extension, or renewal of a Coast Guard collection of information (Collection). The ICR contains information describing the Collection’s purpose, the Collection’s likely burden on the affected public, an explanation of the necessity of the Collection, and other important information describing the Collection. There is one ICR for each Collection. The Coast Guard invites comments on whether this ICR should be granted based on the Collection being necessary for the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing: (1) The practical utility of the Collection; (2) the accuracy of the estimated burden of the Collection; (3) ways to enhance the quality, utility, and clarity of information subject to the Collection; and (4) ways to minimize the burden of the Collection on respondents, including the use of automated collection techniques or other forms of information technology. Consistent with the requirements of Executive Order 13771, Reducing Regulation and Controlling Regulatory Costs, and E:\FR\FM\12JNN1.SGM 12JNN1

Agencies

[Federal Register Volume 84, Number 113 (Wednesday, June 12, 2019)]
[Notices]
[Pages 27339-27341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-12340]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Agency Information Collection Activities: Proposed Collection; 
Comment Request

    In compliance with section 3506(c)(2)(A) of the Paperwork Reduction 
Act of 1995 concerning opportunity for public comment on proposed 
collections of information, the Substance Abuse and Mental Health 
Services Administration (SAMHSA) will publish periodic summaries of 
proposed projects. To request more information on the proposed projects 
or to obtain a copy of the information collection plans, call the 
SAMHSA Reports Clearance Officer on (240) 276-1112.
    Comments are invited on: (a) Whether the proposed collections of 
information are necessary for the proper performance of the functions 
of the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology.

Proposed Project: 2020 National Survey on Drug Use and Health Clinical 
Validation Study and Redesign Field Test (OMB No. 0930-0110)--Revision 
to 2019 NSDUH Collection

    The National Survey on Drug Use and Health (NSDUH) is a survey of 
the U.S. civilian, non-institutionalized population aged 12 years old 
or older. The data are used to determine the prevalence of use of 
tobacco products, alcohol, illicit substances, and illicit use of 
prescription drugs. The results are used by SAMHSA, the Office of 
National Drug Control Policy (ONDCP), federal government agencies, and 
other organizations and researchers to establish policy, direct program 
activities, and better allocate resources.
    2020 NSDUH Main Study--
    NSDUH must be updated periodically to reflect changing substance 
use and mental health issues and to continue producing current data. 
For the 2020 NSDUH main study the following changes from 2019 are 
planned: (1) The addition of lifetime and recency questions about 
vaping anything and vaping nicotine or tobacco; the addition of 
lifetime and recency questions on synthetic marijuana and synthetic 
stimulants; (2) the addition of questions in concordance with the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth 
edition criteria (DSM-5) to measure the occurrence of marijuana 
withdrawal symptoms, occurrence of prescription tranquilizer misuse 
withdrawal symptoms and occurrence of craving for all substances; (3) 
minor revisions to the marijuana marketplace module; and (4) other 
minor wording changes to improve the flow of the interview, increase 
respondent comprehension or to be consistent with text in other 
questions.
    By including these new questions in NSDUH, estimates may be 
generated on the use of these substances among the general population 
and allow SAMHSA to provide national-level estimates among adults and 
adolescents on the use of vaping, synthetic marijuana, and synthetic 
stimulants. In addition, because NSDUH collects demographic, 
socioeconomic, and health information about each respondent, the 
inclusion of these questions would permit a more detailed understanding 
of factors associated with their use.
    The new questions on craving for all substances and withdrawal for 
marijuana/cannabis were added to the 2020 NSDUH main study to reflect 
the updated DSM-5 diagnostic criteria for substance use disorders. 
Questions

[[Page 27340]]

measuring withdrawal for tranquilizers have been added to ensure SUD 
for tranquilizers is accurately assessed as well.
    The marijuana marketplace module (originally dropped in the 2015 
redesign questionnaire) was reinserted in the NSDUH main study 
questionnaire starting in 2018 at the request of ONDCP but was 
unchanged from the version previously used in the 2014 NSDUH. (This 
module was not part of the NSDUH questionnaire from 2015-2017.) This 
module consists of a series of questions that seek to gather data such 
as the location, quantity, cost and type of marijuana being purchased 
across the nation. Revisions have been made to this module for 2020 to 
reflect the availability that marijuana can now be purchased from a 
retail store or dispensary.
    As with all NSDUH/NHSDA surveys conducted since 1999, the sample 
size of the NSDUH main study for 2020 will be sufficient to permit 
prevalence estimates for each of the fifty states and the District of 
Columbia. (Prior to 2002, the NSDUH was referred to as the National 
Household Survey on Drug Abuse (NHSDA).) The total annual burden 
estimate for the NSDUH main study is shown below in Table 1.

                               Table 1--Annualized Estimated Burden for 2020 NSDUH
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Household Screening.............         143,255               1         143,255           0.083          11,890
Interview.......................          69,007               1          69,007           1.000          69,007
Screening Verification..........           4,348               1           4,348           0.067             291
Interview Verification..........          10,351               1          10,351           0.067             694
                                 -------------------------------------------------------------------------------
    Total.......................         143,255  ..............         226,961  ..............          81,882
----------------------------------------------------------------------------------------------------------------

    Clinical Validation Study--
    In addition, a Clinical Validation Study (CVS) is planned to be 
embedded within the first six months of 2020 NSDUH main study data 
collection to assess revisions to the substance use disorders (SUD) 
module to be consistent with the DSM-5. The CVS will examine the 
validity of this revised NSDUH assessment of SUD by administering 
questions to adults and adolescents who will then be interviewed by 
clinical interviewers (who are blinded to the NSDUH main study 
responses) and classified as having or not having substance use 
disorders based on past year DSM-5 disorders, as assessed by the 
Structured Clinical Interview for DSM-5 (SCID-5).
    During CVS data collection from January through June 2020, 
approximately 1,500 NSDUH main study interview respondents will be 
selected for a follow-up clinical interview at the end of the main 
study interview in order to produce a final sample size of 
approximately 825 CVS respondents. These follow-up clinical interviews 
will be conducted via telephone using the SCID-5 within two to four 
weeks following the NSDUH main study interview.
    Many of the procedures and protocols planned for inclusion in this 
CVS are based upon those previously employed as part of the 2018 
National Mental Health Study (approved under OMB No. 0930-0380) and the 
2008-2012 NSDUH Mental Health Surveillance Study (approved as an add-on 
to NSDUH under OMB No. 0930-0110).
    Also, to complete training prior to CVS data collection, each 
clinical interviewer candidate hired must successfully administer the 
follow-up clinical interview with a volunteer respondent. These 70 
certification interviews will be administered in the same manner as CVS 
follow-up clinical interviews.
    The total annual burden estimate for the CVS is shown below in 
Table 2.

                             Table 2--Annualized Estimated Burden for 2020 NSDUH CVS
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Follow-Up Clinical Interviews...             826               1             826            0.83             686
Follow-Up Clinical                            70               1              70            0.83              58
 Certifications.................
                                 -------------------------------------------------------------------------------
    Total.......................             896  ..............             896  ..............             744
----------------------------------------------------------------------------------------------------------------

    Redesign Field Test--
    Also, as part of SAMHSA's ongoing effort to ensure NSDUH continues 
producing current and accurate data, a Redesign Field Test (FT) is 
planned from August through November 2020 to assess potential revisions 
to the NSDUH main study questionnaire. These revisions are designed to 
address changing policy and research data needs; in addition, 
modifications to associated survey materials and methods are designed 
to improve the quality of estimates and the efficiency of data 
collection. Planned FT modifications include changes to respondent 
incentives, respondent materials, the household screening 
questionnaire, the interview questionnaire, and other data collection 
methods.
    The FT is essential for providing a thorough examination of these 
planned changes prior to their deployment on the NSDUH main study to 
determine potential impact across operational and substantive domains, 
including effects on data quality (as measured by outcomes such as unit 
nonresponse, item nonresponse, and survey responses), questionnaire 
timing, data collection efficiency, and possible differences in 
reporting of substance use or mental health items.
    During FT data collection from August through November 2020, 
conducted separately from ongoing 2020 NSDUH main study data collection 
at that time, screenings will be completed

[[Page 27341]]

with approximately 8,110 English-speaking respondents in the contiguous 
United States. (Alaska and Hawaii are excluded from the FT to control 
study costs.) From those screenings, approximately 4,000 respondents, 
as representatives of the civilian, noninstitutional population aged 12 
years old or older, are expected to complete a FT interview using the 
revised questionnaire and materials.
    For the NSDUH FT screening, revisions may include: (1) A revised 
roster structure; (2) various wording edits to improve respondent 
comprehension and flow; (3) the use of revised materials, such as the 
lead letter, study description and question & answer brochure; (4) a 
conditional test of a $5 screening incentive to assess impact on 
response rates; and (5) the inclusion of two outcome questions on past 
month alcohol and past month cigarette use at the end of the screening 
to assess nonresponse bias from the screening incentive.
    For the NSDUH FT interview, revisions may include: (1) A 
conditional test of a $50 interview incentive to assess impact on 
response rates; (2) revisions to the DSM-5-based SUD module as a result 
of prior testing in the CVS; (3) the inclusion of new modules on 
substance use treatment and mental health service utilization; (4) the 
addition of new and/or revised questions on a variety of items such as 
Electronic Nicotine Delivery Systems (ENDS), synthetic drugs, pain and 
sleep, vaping and needle use, and criminal justice; (5) the addition of 
measures of adolescent psychological distress and/or impairment; (6) 
the expansion of suicide items; and (7) other general questionnaire 
revisions such as clarifying wording and terminology, reordering for 
improved question flow, formatting changes, removal of questions with 
low prevalence rates, and other minor updates and revisions.
    The total annual burden estimate for the FT is shown below in Table 
3.

                          Table 3--Annualized Estimated Burden for Redesign Field Test
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Household Screening.............           8,110               1           8,110           0.083             673
Interview.......................           4,000               1           4,000           1.000           4,000
Screening Verification..........             246               1             246           0.067              17
Interview Verification..........             600               1             600           0.067              40
                                 -------------------------------------------------------------------------------
    Total.......................           8,110  ..............          12,596  ..............           4,730
----------------------------------------------------------------------------------------------------------------

    Send comments to Janet Heekin, SAMHSA Reports Clearance Officer, 
Room 15E21B, 5600 Fishers Lane, Rockville, MD 20857 or email a copy at 
[email protected].
    Written comments should be received by August 12, 2019.

    Dated: June 6, 2019.
Carlos Castillo,
Committee Management Officer.
[FR Doc. 2019-12340 Filed 6-11-19; 8:45 am]
 BILLING CODE 4162-20-P